Evidence map›Paper›PMID 39928372›Full record

ArticleRheumatology (Oxford, England)2025

Approach to Janus kinase inhibition for juvenile dermatomyositis among CARRA and PReS providers.

Matthew A Sherman, Rebecca Nicolai, Emily K Datyner, Silvia Rosina, Angela Hamilton, Kaveh Ardalan, Brigitte Bader-Meunier, Amanda G Brown, Marc H A Jansen, Susan Kim and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Matthew A ShermanDivision of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-5448-1538
Rebecca NicolaiDivision of Rheumatology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Emily K DatynerDepartment of Pediatric Rheumatology, Vanderbilt University Medical Center, Nashville, TN, USA.
Silvia RosinaUOC Reumatologia E Malattie Autoinfiammatorie, IRCCS Istituto Giannina Gaslini, Genoa, Italy.ORCID 0000-0002-3667-6155
Angela HamiltonDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA.
Kaveh ArdalanDepartment of Pediatrics, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0001-5075-8846
Brigitte Bader-MeunierDepartment of Pediatric Immunology and Rheumatology, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Amanda G BrownDepartment of Rheumatology, Children's Hospital of Arkansas, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Marc H A JansenDepartment of Paediatric Immunology & Rheumatology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.
Susan KimDepartment of Pediatrics, University of California, San Francisco, CA, USA.ORCID 0000-0003-2159-8059
Bianca LangDepartment of Pediatrics, Dalhousie University and IWK Health, Halifax, NS, Canada.
Raquel Campanilho-MarquesDepartment of Rheumatology, Unidade Local de Saúde de Santa Maria, Lisbon, Portugal.
Liza J McCannDepartment of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.
Helga SannerDepartment of Rheumatology, Oslo University Hospital, Oslo, Norway.
Saskia R VeldkampCenter for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID 0000-0002-1626-353X
Meredyth G Ll WilkinsonInfection, Immunity and Inflammation Research and Teaching Department, UCL Great Ormond Street Institute of Child Health, London, UK.ORCID 0000-0002-7972-8066
Belina Y YiDepartment of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Hanna KimJuvenile Myositis Pathogenesis and Therapeutics Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-0595-6533
Stacey E TarvinDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA.
Charalampia PapadopoulouRare Diseases Theme NIHR Biomedical Research Centre, Great Ormond Street Hospital, London, UK.
CARRA JDM Therapeutics Workgroup and the PReS JDM Working Party

Funding

Musculoskeletal and Skin DiseasesNational Institute of ArthritisNIH HHS AR041215
6 · The paper itself

Abstract

objectivesJanus kinase inhibition (JAKi) has been proposed as a treatment for idiopathic inflammatory myopathies to target increased interferon signalling. Predominantly retrospective reports have demonstrated effectiveness of JAKi in refractory JDM. However, JAKi remains an off-label treatment for JDM and there may be variation in use worldwide. An international survey was conducted to investigate approaches to JAKi for JDM.

methodsThe Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Therapeutics workgroup and core members of the Paediatric Rheumatology European Society (PReS) JDM working party devised an electronic survey to assess the use of JAKi in JDM. CARRA and PReS members were invited by e-mail to complete the survey.

resultsThere were 229 respondents (18%), with 50% from the USA and 29% from Europe. One hundred and fifty had used JAKi for over 450 patients with JDM; among them, 77% noted clinical improvement in most or all patients and 17% reported side effects. The highest ranked perceived barriers to JAKi use were lack of clinical data and inability to obtain insurance approval. The highest ranked clinical indications for starting JAKi were refractory skin disease, refractory muscle disease, inability to wean steroids and intolerance to other steroid-sparing agents.

conclusionPaediatric rheumatologists use JAKi off-label for refractory JDM. Most providers noted clinical improvement in their patients. Barriers to JAKi use include lack of clinical data and insurance coverage. Clinical trials are needed to provide better data on the efficacy and safety of JAKi.

Indexed as

DermatomyositisJanus Kinase InhibitorsPractice Patterns, Physicians'ChildEuropeFemaleHumansMaleOff-Label UseRheumatologySurveys and QuestionnairesUnited StatesJanus Kinase InhibitorsJanus kinase inhibitorsjuvenile dermatomyositispediatric rheumatology

Identifiers

PMID39928372
PMCPMC12316366

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.